ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.

TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.

Tuesday, TD Cowen reaffirmed its Buy rating and $285.00 price target on ICON plc shares (NASDAQ:ICLR), following the company's financial guidance. According to InvestingPro analysis, ICON ...

Full year 2025 financial guidance excludes any potential share repurchase or additional M&A activity. CEO Dr. Steve Cutler commented, "ICON continues to navigate dynamic clinical development ...